title: Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
abstract: In this study, the expression of DNA excision repair cross-complementing gene 1 (ERCC1) in local advanced nasopharyngeal carcinoma has been correlated with the efficacy of concurrent chemoradiotherapy. A total of 76 patients diagnosed with undifferentiated nasopharyngeal carcinoma diagnosed by nasopharyngeal biopsy and undergoing single-agent cisplatin chemotherapy (80 mg/m(2)) with concurrent radiotherapy (on the first, twenty-second, and forty-third day, 5 times per week, mean dose 74 Gy, range 70-78 Gy) at the Affiliated Cancer Hospital of Guangxi Medical University between January and December 2010 were included. After chemoradiotherapy, outcomes and long-term survival were evaluated. Immunohistochemistry was used to detect expression of ERCC1 protein in nasopharyngeal carcinoma. The relationship between the expression of ERCC1 and efficacy of concurrent chemoradiotherapy and long-term survival were analyzed. ERCC1 was expressed in 42.1% of cases. The expression of ERCC1 was correlated with T stage and clinical staging (P < 0.05), but not with gender, age, or N stage. The response rate in the ERCC1-positive and ERCC1-negative groups was 75.0% and 97.7%, respectively (P < 0.05). In the 72 cases with follow-up available, 1-, 2-, and 3-year survival rates were 91.0, 83.3, and 79.0%; they were 92.4, 87.8, 80.5%, respectively, in the ERCC1-positive group, and 87.9, 77.4, 77.4%, respectively, in the ERCC1-negative group. The expression of ERCC1 may be a sensitive prognostic indicator of concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma.
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: R
authors.initials: R
authors.lastname: Liang
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Liu
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: X L
authors.initials: XL
authors.lastname: Liao
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: C L
authors.initials: CL
authors.lastname: Yuan
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: S N
authors.initials: SN
authors.lastname: Liao
authors.affiliation: Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Li
mesh_terms: D000328:Adult; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D018572:Disease-Free Survival; D004720:Endonucleases / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy; D011379:Prognosis
chemical_list: D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin